Wayne Wilson - Hologic Independent Director

HOLX Stock  USD 77.96  0.61  0.79%   

Director

Mr. Wayne Wilson is an Independent Director of Hologic Inc. Mr. Wilson became one of our directors effective upon our merger with Cytyc in October 2007 having previously served as a director of Cytyc since 2003. He was an independent business advisor since 2002. From 1995 to 2002 He served in various roles including as President Chief Operating Officer and Chief Financial Officer at PC Connection Inc. a Fortune 1000 direct marketer of information technology products and services. From 1986 to 1995 he was a partner in the assurance and advisory services practice of Deloitte Touche LLP. He also serves as a director of ARIAD Pharmaceuticals Inc. Edgewater Technology Inc. and FairPoint Communications Inc. Mr. Wilsons qualifications to serve on the Board include his extensive experience in financial accounting and reporting and his ability to evaluate financial results and generally oversee the financial reporting process of a publicly traded corporation. since 2007.
Age 65
Tenure 17 years
Address 250 Campus Drive, Marlborough, MA, United States, 01752
Phone508 263 2900
Webhttps://www.hologic.com

Wayne Wilson Latest Insider Activity

Tracking and analyzing the buying and selling activities of Wayne Wilson against Hologic stock is an integral part of due diligence when investing in Hologic. Wayne Wilson insider activity provides valuable insight into whether Hologic is net buyers or sellers over its current business cycle. Note, Hologic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hologic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Hologic Management Efficiency

The company has return on total asset (ROA) of 0.0649 % which means that it generated a profit of $0.0649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1057 %, meaning that it created $0.1057 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.09 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, Hologic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 5.1 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 3 B in 2024.
The company currently holds 2.82 B in liabilities with Debt to Equity (D/E) ratio of 0.57, which is about average as compared to similar companies. Hologic has a current ratio of 3.82, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Hologic until it has trouble settling it off, either with new capital or with free cash flow. So, Hologic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hologic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hologic to invest in growth at high rates of return. When we think about Hologic's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Jack PeurachEkso Bionics Holdings
48
Matthew RosenbergNephros
33
Ann CooksonEkso Bionics Holdings
N/A
Alfred VargasNephros
N/A
Stanley SternEkso Bionics Holdings
60
Alisa LaskNephros
N/A
Thomas SchreckEkso Bionics Holdings
60
Theodore WangEkso Bionics Holdings
51
Thomas GwydirNephros
N/A
Howard PalefksyEkso Bionics Holdings
N/A
Dan BorenEkso Bionics Holdings
40
Arthur AmronNephros
61
Oliver SpandowNephros
N/A
Marilyn HamiltonEkso Bionics Holdings
64
Ted WangEkso Bionics Holdings
50
Paul MieyalNephros
45
Andrew HuntWarby Parker
N/A
Malcom PersenNephros
60
Amy WendellEkso Bionics Holdings
56
Charles LiEkso Bionics Holdings
N/A
Moshe PintoNephros
N/A
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for womens health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts. Hologic operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 6705 people. Hologic (HOLX) is traded on NASDAQ Exchange in USA. It is located in 250 Campus Drive, Marlborough, MA, United States, 01752 and employs 6,990 people. Hologic is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Hologic Leadership Team

Elected by the shareholders, the Hologic's board of directors comprises two types of representatives: Hologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hologic. The board's role is to monitor Hologic's management team and ensure that shareholders' interests are well served. Hologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
Wayne Wilson, Independent Director
Namal Nawana, Director
Peter Dunne, Senior Resources
Sally Crawford, Independent Director
Erik Anderson, Division Solutions
Mark Irving, VP Secretary
Jay Stein, Co-Founder, Chairman Emeritus, Chief Technical Officer and Sr. VP
Stephen MacMillan, Chairman, CEO and Pres
Sanjay Prabhakaran, Regional President - Asia
Claus Egstrand, Senior Vice President General Manager - International
Ludwig Hantson, Director
Jennifer Schneiders, President Solutions
Samuel Merksamer, Independent Director
Christiana Stamoulis, Director and Member of Corporate Devel. Committee
Robert McMahon, CFO
Essex Mitchell, Chief Officer
Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
Karleen Oberton, CFO, Chief Accounting Officer
Monica Berthelot, VP Staff
Thomas West, Division President of Diagnostics Solutions
Eric Compton, COO
Paul Malenchini, Chief Officer
Lawrence Levy, Independent Director
Benjamin Cohn, Principal Chief Accounting Officer
Elaine Ullian, Independent Director
Kevin Thornal, Group Solutions
Amy Wendell, Director
Scott Garrett, Independent Director
Peter Valenti, Division President- Breast and Skeletal Health
Nancy Leaming, Independent Director
Scott Christensen, Quality Chain
Elisabeth Hellmann, Sr Communications
John Griffin, General Counsel
Allison Bebo, Senior Vice President - Human Resources
Mike Kelly, Chief Affairs
Charles Dockendorff, Director
Michael Watts, Vice President IR Contact Officer
Ryan Simon, Vice Relations
Jonathan Christodoro, Independent Director
Al Kildani, Senior Director - Investor Relations
Brandon Schnittker, Division Solutions

Hologic Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hologic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hologic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hologic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hologic Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hologic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Hologic Stock please use our How to Invest in Hologic guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Hologic Stock analysis

When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stocks Directory
Find actively traded stocks across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Hologic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hologic. If investors know Hologic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hologic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.373
Earnings Share
2.11
Revenue Per Share
16.228
Quarterly Revenue Growth
(0.06)
Return On Assets
0.0649
The market value of Hologic is measured differently than its book value, which is the value of Hologic that is recorded on the company's balance sheet. Investors also form their own opinion of Hologic's value that differs from its market value or its book value, called intrinsic value, which is Hologic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hologic's market value can be influenced by many factors that don't directly affect Hologic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hologic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hologic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hologic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.